Ose Pharma International selects 70 centers for phase 3 Tedopi trial
Thursday, December 24, 2015
Ose Pharma International SA selects 70 international clinical centers to participate in its pivotal phase 3 trial of Tedopi for patients diagnosed with advanced non-small cell lung cancer.
